Mon, Dec 29, 2014, 4:38 AM EST - U.S. Markets open in 4 hrs 52 mins


% | $
Quotes you view appear here for quick access.

Taro Pharmaceutical Industries Ltd. Message Board

  • valery164 valery164 May 27, 2014 5:44 PM Flag

    Earning released.

    Not bad and not great either.
    Less revenue & EPS then Q3 & Q4 but Q1 was always a week quarter . last year Q1 revenue was 11.5% less then previous Q4 , similar this time 12%.
    EPS $2.1 versus $1.13 in 2013, so trailing EPS above $8 , there is a possibility to have 2014 EPS close to $10.
    Pipeline is healthy.
    Still undervalued at least by 30%-40% w/o any big catalyst (IMHO)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • you gotta be kidding...when you say undervalued by 30-40%.

      -Novexatin itself could be valued in billions considering the competitive advantages
      - row value for taro's 200 products could be huge considering the growth in those markets
      - ackman's presentation applies 20 times ebitda for topical generic business
      - mylan purchased niche generic pharma agila at 18 times ebitda

      please let me know how much taro's fair value is

145.01+0.43(+0.30%)Dec 26 4:02 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.